MannKind Starts Inhale-Afrezza Pediatric Trial for New Type 1 Diabetics (MNK.US)

MannKind (MNK.US) announced it has initiated the first pediatric trial of Afrezza inhalation insulin in patients with newly diagnosed Type 1 diabetes. The single-blind, placebo-controlled study will enroll 60 patients aged 6-18 across the U.S., with results expected by the end of 2026. The trial evaluates safety, tolerability, and glucose control, aiming to support potential regulatory approval by 2027. Afrezza, launched in 2016, is approved for adults with Type 2 diabetes.